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Purpose: Since its introduction in 1991, ultrasound guided compression repair of post- 
catheterization femoral artery pseudoaneurysms has been shown to be effective. 
Disadvantages of ultrasound guided compression repair include patient discomfort dur- 
ing compression, inability to treat noncompressible pseudoaneurysms, prolonged use of 
ultrasound equipment and personnel, imited success with patients being treated with 
anticoagulants, and some early recurrences. We conducted a prospective study to evalu- 
ate a new method of treating femoral pseudoaneurysms, percutaneous ltrasound guid- 
ed thrombin injection. 
Methods: Under duplex ultrasound guidance, a 22- or 25-gauge needle was percuta- 
neously positioned within the pseudoaneurysm. Without compressing the pseudo- 
aneurysm, 0.5 to 1 ml thrombin solution (1000 U/ml)  was injected to induce throm- 
bosis. Early in the study, the procedure was modified to allow more than one injection. 
After successful thrombosis, the patients were kept at rest in bed for at least 1 hour. 
Duplex ultrasound examination was repeated in 1 to 4 days. Distal pulses and ankle- 
brachial indexes were measured before and after the procedure. 
Results: Twenty of 21 consecutive pseudoaneurysms were successfully treated with 
thrombin injection. Fifteen pseudoaneurysms thrombosed immediately (<20 seconds) 
after one injection. The other five had partial thrombosis after one injection and com- 
plete thrombosis immediately after a second injection. The one failure occurred in a 
patient who had only one injection and then underwent subsequent ultrasound guided 
compression repair, which failed. No patient required sedation or analgesia during 
thrombin injection. There were no procedure-related complications and no recurrences. 
Conclusions: Percutaneous ltrasound guided thrombin injection appears to be a safe and 
expeditious method for treating postcatheterization femoral pseudoaneurysms. It has 
significant advantages with respect to ultrasound guided compression repair or surgical 
repair. (J Vase Surg 1998;27:1032-8.) 
The incidence of pseudoaneurysms after percu- 
taneous femoral artery catheterizations has 
increased recently with the use of  larger catheters 
for various interventional procedures and the more 
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frequent use of  continued anticoagulation. Since 
its introduction in 1991,1 ultrasound guided com- 
pression repair (UGCR) has become the initial 
mode of treatment. The method requires sponta- 
neous thrombosis of  blood within the aneurysmal 
sac while flow is temporarily arrested by compres- 
sion of the neck of  the pseudoaneurysm with the 
ultrasound transducer. Color-f low duplex ultra- 
sound allows this cessation of  flow to be visualized 
with flow through the native circulation moni- 
tored at the same time. Many of  these pseudoa- 
neurysms can be successfully occluded by this 
technique. The compression time required for suc- 
cessful thrombosis varies from I0 minutes to as 
long as 300 minutes in various series, and mean 
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compression times of 30 to 104 minutes have been 
reported. 2q0 
We and others have found that the failure rate of 
this treatment method is significantly higher for 
patients who are receiving anticoagulants.2,3,6,8,11 This 
is understandable cause spontaneous thrombosis 
less likely to be achieved with anticoagulated blood. It 
is therefore r asonable to assume that hypercoagulable 
blood within a pseudoaneurysm would be more likely 
to thrombose than would normal or anticoagulated 
blood. This study was undertal<en to prospectively 
evaluate a new method of treating postcatheterization 
femoral pseudoaneurysms, percutaneous ltrasound 
guided thrombin injection. 
PATIENTS AND METHODS 
The study was conducted between February 1996 
and July 1997 and approved by the Institutional 
Review Board. Informed consent was obtained from 
all subjects. All adult patients with postcatheterization 
femoral artery pseudoaneurysms were eligible for 
study. Patients with evidence of local infection, over- 
lying sldn or distal imb ischemia, or a history of aller- 
gic responses to thrombin or bovine products were 
excluded. 
During the study period, 27 femoral pseudo- 
aneurysms were diagnosed in 26 patients (one 
patient had bilateral pseudoaneurysms). No patient 
was excluded for the criteria mentioned previously. 
Six patients did not undergo thrombin injection 
because of referring physician preference: three 
underwent immediate surgical repair, one under- 
went repair during a planned femorofemoral bypass, 
and two underwent successful UGCR. Five patients 
entered the study after unsuccessful attempts at 
UGCR. Thus 20 consecutive patients with 21 
pseudoaneurysms were enrolled in the study. 
There were 10 male and 10 female patients, with 
a mean age of 66 years (range 40 to 84 years). All 
had undergone catheterization 1 to 21 days (mean 6 
days) before the study. Catheter sheath size ranged 
from 6F to 9F. Ten patients underwent diagnostic 
catheterization ly and 10 underwent interven- 
tional procedures. Nine patients underwent translu- 
minal coronary angioplasty, with stent placement in
three and thrombolytic therapy in one. The patient 
with bilateral pseudoaneurysms received throm- 
bolytic therapy and angioplasty for a popliteal occlu- 
sion. Seven pseudoaneurysms in six patients were 
injected while the patients were on anticoagulant 
regimens of heparin, coumadin, or both. Five addi- 
tional patients were placed on anticoagulant regi- 
mens after thrombin injection. 
Diagnostic duplex ultrasound was performed 
with an ATL HDI 3000 (Advanced Technology 
Laboratories, High Definition Image, Bothell, 
Wash.) or an Acuson 128XP (Acuson Computed 
Sonography, Mountain View, Calif.) with a 4 to 7 
MHz or 5 MHz linear-array transducer. Nineteen 
pseudoaneurysms arose from the common femoral 
artery, one arose from the superficial femoral artery, 
and one arose from both the superficial and deep 
femoral arteries. Four pseudoaneurysms had associ- 
ated arteriovenous fistulas. The width and depth 
were measured on a transverse image through the 
center of the pseudoaneurysm and the length was 
measured on a longitudinal image. The width and 
length of the pseudoaneurysmal neck were record- 
ed. The status of pulses and the Doppler-derived 
anlde-brachial index of both legs were determined 
before and after the procedure. 
A solution of bovine thrombin (1000 U/ml) was 
prepared fresh by adding 1 ml sterile normal saline 
solution to a 1000 U vial ofthrombin powder. This 
solution was loaded into a 3 ml syringe attached to 
a 22- or 25-gauge hypodermic needle. For patients 
whose pseudoaneurysm was relatively distant from 
the sldn surface, a 3.5-inch spinal needle was used. 
The ultrasound transducer was positioned direct- 
ly over the pseudoaneurysm. The sldn adjacent to the 
transducer was prepped with alcohol. The needle tip 
was inserted into the center of the aneurysm under 
ultrasound guidance, with color flow turned off to 
better visualize the needle. With color flow back on, 
0.5 to 1 ml thrombin solution was injected into the 
pseudoaneurysm during several seconds and the nee- 
die was removed. Continuous ultrasonographic imag- 
ing allowed real-time monitoring ofpseudoaneurysm 
thrombosis. Compression was not applied. After the 
second case, the protocol was modified toallow addi- 
tional injections of 0.5 to 1 ml if the aneurysm was 
still patent after the initial injection. 
Successfully treated patients were kept at rest in 
bed for at least 1 hour, and outpatients were not 
admitted. All patients underwent imaging again at 
least 24 hours later to detect spontaneous thrombo- 
sis or recurrence. Pulse measurements of the extrem- 
ity were again performed at that time. 
RESULTS 
Percutaneous ltrasound guided thrombin injec- 
tion was technically feasible in all 21 pseudoa- 
neurysms. Twenty pseudoaneurysms (95%) were suc- 
cessfully occluded by thrombin injection. Fifteen 
pseudoaneurysms thrombosed immediately (<20 
seconds) after one injection. Five had partial throm- 
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bosis after one injection and complete thrombosis 
immediately after a second injection. 
The one failure occurred in a patient who had 
only one injection. The pseudoaneurysm had two 
necks, arising from the superficial and deep femoral 
arteries, and an arteriovenous fi tula into the com- 
mon femoral vein. There was partial thrombosis 
after thrombin injection. Our protocol at the time 
was to perform UGCR ifa single thrombin injection 
was not successful. UGCR was attempted for 40 
minutes, without success. Imaging 3 days later 
showed persistent flow in the aneurysm and fistula, 
and the patient underwent surgical repair. 
Early in the study we found that 25-gange nee- 
dies were rather difficult o image, so we switched to 
22-gauge needles. Ultrasound guidance made it 
easy to place the needle within even small and deeply 
situated pseudoaneurysms. The presence of throm- 
bin solution in the needle further improved visual- 
ization of the needle tip because an echogenic 
thrombus would form on the bevel when it entered 
the pseudoaneurysm. During the injection of 
thrombin, the color-flow image displayed a mosaic 
of color as a result of turbulence and motion artifact. 
As this subsided, thrombus formation could be 
clearly seen. The thrombus usually appeared to be 
more echogeuic than is seen after UGCR or sponta- 
neous thrombosis (Fig. 1). 
We had prospectively collected numerous data 
on patient, catheterization, a d aneurysm character- 
istics, with plans to identify determinants of success 
or failure of thrombin injection. With one failure 
and 20 successes, it was not possible to identify any 
features that would allow us to predict successful 
injection. However, if the 15 pseudoaneurysms that 
had complete thrombosis after one injection are 
compared with e six pseudoaneurysms that had 
partial thrombosis after one injection, the difference 
in pseudoaneurysm volume (length × width × 
depth) does approach statistical significance. In 
those pseudoaneurysms that thrombosed after one 
injection, the mean volume was 14.4 * 17.0 cm 3, 
compared with 35.4 _+ 31.3 cm 3 in aneurysms that 
persisted after one injection (p = 0.059, t test). Thus 
larger pscudoaneurysms probably require more 
thrombin than do smaller ones. In fact, the one 
unsuccessfully treated pseudoaneurysm was the 
largest in the study (82.1 cm3), whereas the six 
smallest aneurysms (volumes <4 cm3), thrombosed 
after injection of only 0.5 ml thrombin. On the 
other hand, anticoagulation status or pseudo- 
aneurysm neck diameter did not seem to influence 
how much thrombin was necessary for complete 
thrombosis (Table I). 
None of the patients noted any major discomfort 
from the procedure, nor did any require sedation or 
analgesia. All palpable pedal pulses before thrombin 
injection were present after thrombin injection, and 
there were no significant changes in anlde-brachial 
indexes. 
There were no procedure-related complications. 
One patient died of cardiac complications 10 days 
after successful thrombin injection. She had been 
admitted with an acute myocardial infarction and 
underwent coronary angioplasty. One week after 
treatment of the pseudoaneurysm, heparin-induced 
thrombocytopenia and coronary thrombosis devel- 
oped. For the remaining 18 successfully treated 
patients, the mean time until discharge was 3.8 days 
(range 0 to 11 days). Four patients were treated as 
outpatients, four patients were discharged the next 
day, and one patient was discharged in 2 days. 
Duplex examination was repeated in all patients after 
1 to 4 days and did not reveal any recurrent 
pseudoaneurysms. All patients have had clinical fol- 
low-up by their physicians for at least 3 months 
without further problems. 
DISCUSSION 
UGCR of postcatheterization femoral pseudo- 
aneurysms has been shown to be safe and effective, 
with an overall success rate of about 75%. It has 
become the initial treatment of choice in most cen- 
ters. The procedure is relatively simple. The ultra- 
sound transducer is used to compress the pseudoa- 
neurysm neck and arrest flow, so that blood within 
the aneurysmal cavity becomes stagnant and eventu- 
ally clots.1 Because of several significant disadvan- 
tages of UGCR, we conceived a new method of 
treatment and evaluated it in this prospective study. 
Our early results suggest hat percutaneous ltra- 
sound guided thrombin injection is a safe and 
extremely efficacious way to treat postcatheteriza- 
tion femoral pseudoaneurysms and that it obviates 
some of the problems encountered with UGCtL 
UGCR requires the ability to arrest flow within 
the pseudoaneurysm. Larger series report that as 
many as 10% of patients cannot be treated with 
UGCR because flow cannot be arrested.l,2,7,12 
Some patients have pseudoaneurysm necks that are 
not compressible or cannot be compressed without 
collapsing the underlying native artery. Other 
patients technically can have compression but do not 
tolerate it because of severe pain, despite analgesia 
and sedation, or because of vasovagal reactions. 
Patients have been given spinal or general anesthesia 
for UGCR.2, 5 Because thrombin injection does not 
require compression, no patient in this study was 
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Fig. 1, Duplex ultrasound of a femoral pseudoaneurysm. A, Color-flow image demonstrates 
typical swirling flow in the pseudoaneurysm cavity. Note clock in upper right corner. 
B, This image, taken 18 seconds later with color flow turned off, shows the tip of a 22-gauge 
needle in the left lower portion of the pseudoaneurysm. After placement of the needle, color 
flow is turned back on and thrombin is injected. Continued 
excluded because of inability to compress or inabili- 
ty to tolerate compression. Discomfort from our 
procedure was minimal, and no analgesia or sedation 
was required. 
Continued anticoagulation has been shown in 
most reports to significantly decrease the success 
rate of  UGCR.2,3,6,8,11 This makes intuitive sense. 
Because the final pathway of  blood coagulation is 
the generation of  thrombin, the addition of suffi- 
cient amounts of thrombin to anticoagulated blood 
will reliably induce thrombosis. Six of  seven 
pseudoaneurysms in patients who were on anticoag- 
ulant regimens at the time ofthrombin injection had 
successful thrombosis. Mthough our experience 
with anticoagulation is limited, we predict that 
thrombin injection will be effective in most cases. 
Continued anticoagulation also seems to increase 
the recurrence rate after successful UGCR. Cox et 
al. 13 found recurrent pseudoanenrysms in 20% of 
their patients on anticoagulant regimens, versus 6% 
without anticoagulation. Overall recurrence rates of 
4% to 11% have been reported in the largest series, 
most within 24 hours.2,7,9,13 We had no early recur- 
rences despite early mobilization and discharge and 
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Fig. 1. Continued Duplex ultrasound of a femoral pseudoaneurysm. C, Color-flow image 21 
seconds later demonstrates p eudoaneurysm cavity completely filled with echogenic thrombus. 
Tab le  I. Selected characteristics of pseudoaneurysms, li ted by increasing size 
Volume of Width of Volume of No, Anticoagulated 
aneurysm aneurysmal neck  thrombin injected of at thrombin 
Case (ml) (ram) (ml) injections injection Outcome 
1 1.0 4 0.5 1 Yes Successful 
2 1.3 4 0.5 1 No Successfifl 
3 1.9 6 0.5 1 No Successful 
4 2.0 7 0.5 1 Yes Successful 
5 3.0 6 0.5 1 No Successful 
6 3.8 8 0.5 1 Yes Successful 
7 7.1 1 1 1 No Successful 
8 9.4 7 1.5 2 No Successful 
9 11.1 4 2 2 No Successful 
i0 iI.6 5 i 1 No Successfifl 
i 1 11.9 5 1 1 No Successful 
12 I4.6 4 1 1 Yes Successful 
13 16.7 4 1 1 No Successful 
14 16.8 5 1.5 2 No Successful 
15 22.4 5 1 1 Yes Successfnl 
16 25.4 4 1 1 Yes Successful 
17 25.6 4 2 2 No Successful 
18 26.3 10 1 i No Successful 
19 66.6 5 1 1 No Successful 
20 67.2 9 2 2 No Successful 
21 82.1 5 1 1" Yes Not successful 
*Had only one injection, per protocol at that time. 
despite postprocedural anticoagulation in 10 patients 
(11 pseudoaneurysms).  The injection of  th rombin  
may make the resulting hematoma more stable. It 
was our impression that the thrombus appeared more 
echogenic on u l t rasound,  which may be a reflection 
of  altered f ibrin formation.  Studies with f ibrin 
sealants have shown that increasing the thrombin  
concentration yields a clot that has a more dense fib- 
ril structure and increased tensile strength. 14 This 
may translate into lower recurrence rates after 
thrombin injection than after UGCR~ 
The one pseudoaneurysm in which thrombosis 
failed was large, had an arteriovenous fistula, and 
was anticoagulated at the time of injection, all which 
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may be factors that make success less likely. 
However, we believe that the reason for failure was 
that we injected only once (per our protocol at the 
time) and that additional injections would have led 
to complete thrombosis. We recommend initial 
injections of 0.5 to 1 ml and then reinjection of 
another 0.5 to 1 ml if part of the aneurysm is still 
patent. A small aneurysm, less than 1 cm in diame- 
ter, may need less than 0.5 ml because the volume of 
the aneurysm itself is less than 1 ml. 
During insertion of the needle into the pseudo- 
aneurysm, it is helpful to have the thrombin solution 
loaded beforehand on a syringe and flushed through 
the needle. We noticed that sometimes the needle 
itself was not as easily seen as was the small clot that 
formed on the bevel of the needle when it entered 
the aneurysm. Because lmowledge of the needle tip 
location is essential to avoid injection into the 
underlying artery, this additional visual cue is useful. 
However, another technique for localizing the tip is 
available. Liau et al.15 recently described a similar 
method for treating pscudoaneurysms, with success 
in five patients. Their procedure involves placing a 
catheter into the pseudoaneurysm. Because the 
catheter apparently is not visible on ultrasound, they 
inject saline solution containing micro-air bubbles 
to identify the location of the catheter tip before 
injecting the thrombin solution. 
We injected thrombin at a concentration of 
1000 U/ml, for a total dose of as much as 2000 U. 
The particular dose ofthrombin was chosen for sev- 
eral reasons. The manufacturers' recommended 
dilution for topical use is 1000 U/ml. Animal stud- 
ies have shown that intravenous infusion of throm- 
bin at a rate of 5 U/kg/min  for 10 to 15 minutes 
has minimal effects. 16-18 Intravascular injection of 
thrombin in concentrations of 100 to 1000 U/ml,  
with total doses as great as 10,000 U, have been 
used clinically by several investigators in treating 
esophageal 19 and gastric varices 2° and arterial 
aneurysms 21-23 without significant side effects. 
Intravariceal injection of 15,000 U did result in 
temporary side effects of headache, hypotcnsion, 
and a disseminated intravascular coagulation-like 
laboratory profile, which resolved completely after 
the procedure. 24 We therefore considered that 
using 1 to 2 ml thrombin at 1000 U/ml would be 
safe and effective. 
There were no complications related to the pro- 
cedure. The biggest concern for us when we started 
the study was the risk of native arterial thrombosis 
from thrombin lealdng out of the pseudoaneurysm 
into the feeding artery. For this reason we moni- 
tored the status of distal pulses and Doppler pres- 
sures carefully, and we found no evidence of throm- 
boembolic events. We believe that when thrombin 
of sufficiently high concentration is injected into the 
aneurysm it immediately forms a clot and is trapped 
within the cavity. Because the hole in the artery (and 
in the vein for an arteriovenous fi tula) has been cre- 
ated by needles and catheters, it is rarely more than 
a few millimeters wide and is unlikely to allow a large 
clot to pass through it. If thrombin itself were to 
somehow leal< into the artery, it could be effectively 
neutralized by dilution and by anticoagulant factors 
on the endothelium and in the circulating blood, 
such as thrombomodulin a d antithrombin III.25, 26 
Surveillance for this kind of complication seems 
advisable. 
The patient who died had been receiving 
heparin before and after thrombin injection. Seven 
days after thrombin injection, a drop in the platelet 
count was noted and the heparin infusion was 
stopped. Heparin-induccd thrombocytopenia w s 
documented by platelet aggregometry and sero- 
tonin-release assay. Three days later the patient had 
a second myocardial infarction and died. We have 
found no report in the literature that suggests that 
thrombin can cause heparin-induced thrombocy- 
topenia, although large intravenous doses ofthrom- 
bin (300 U/kg) have been shown in animals to 
cause acute disseminated intravascular coagulation 
with thrombocytopcnia and abnormal bleeding. 27 
We therefore believe that this complication was not 
caused by thrombin injection. In our small series, 
thrombin injection does appear to be a safe and 
effective procedure. 
Finally, UGCR is labor-intensive and thrombin 
injection is not. With a little experience, needle 
placement usually tal;es less than a minute; 20 sec- 
onds later, the pseudoaneurysm hasbeen treated. In 
the current era of cost-containment, this may the 
biggest advantage of all. 
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DISCUSSION 
Dr. tL Clement Darling, I I I  (Albany, N.Y.). That is a 
fascinating procedure that looks like it may have some 
appfication. When Allastair Karmody was trying to find a 
nonoperative method or a minimally invasive method for 
thrombosing aneurysms, he injected an excluded aneurysm 
sac with thrombin once and had a horrifying systemic reac- 
tion. I wonder if you have seen any systemic reactions from 
the use of thrombin in the circulation? 
Dr. Steven S. Kang. We have not had any systemic reac- 
tions or even local distal fimb reactions. This may be related 
to whether or not the thrombin leaks out into the circulation 
at all and related to the amount of thrombin that enters the 
circulation. In animal studies, intravenous infusions of 
thrombin at 5 units/kg/minute are tolerated for up to 15 
minutes with no clinical effects. Fibrinogen and platelet 
comats will be decreased. If this infusion is performed for 60 
minutes, then the patient may have hypotension and dis- 
seminated intravascular coagulation. In clinical experience 
with endoscopic esophageal varices injection of thrombin, 
up to I5,000 units have been injected. At that point, patients 
may have systemic effects, mainly hypotension. At doses also 
up to I0,000, no systemic effects have occurred. 
